---
layout: post
title: "Rare Disease Endpoint Advancement Pilot Program Workshop: Novel Endpoints for Rare Disease Drug Development; Public Workshop; Request for Comments"
date: 2026-02-05 18:55:14 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-08066
original_published: 2023-04-17 00:00:00 +0000
significance: 8.00
---

# Rare Disease Endpoint Advancement Pilot Program Workshop: Novel Endpoints for Rare Disease Drug Development; Public Workshop; Request for Comments

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** April 17, 2023 00:00 UTC
**Document Number:** 2023-08066

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing a public workshop entitled "Rare Disease Endpoint Advancement Pilot Program Workshop: Novel Endpoints for Rare Disease Drug Development." Convened by the Duke-Robert J. Margolis, MD Center for Health Policy (Duke-Margolis) and supported by a cooperative agreement between FDA and Duke-Margolis, the workshop will include discussions of the Rare Disease Endpoint Advancement (RDEA) Pilot Program and novel endpoint development for rare disease drug development.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/04/17/2023-08066/rare-disease-endpoint-advancement-pilot-program-workshop-novel-endpoints-for-rare-disease-drug)
- API: https://www.federalregister.gov/api/v1/documents/2023-08066

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
